Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income: 2016-2024

Historic Other Non Operating Income for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$517,000.

  • Akebia Therapeutics' Other Non Operating Income rose 41.18% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $158,000, marking a year-over-year increase of 85.88%. This contributed to the annual value of -$517,000 for FY2024, which is 158.29% down from last year.
  • As of FY2024, Akebia Therapeutics' Other Non Operating Income stood at -$517,000, which was down 158.29% from $887,000 recorded in FY2023.
  • Akebia Therapeutics' Other Non Operating Income's 5-year high stood at $3.1 million during FY2022, with a 5-year trough of -$517,000 in FY2024.
  • In the last 3 years, Akebia Therapeutics' Other Non Operating Income had a median value of $887,000 in 2023 and averaged $1.2 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first spiked by 333.75% in 2020, then crashed by 158.29% in 2024.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Other Non Operating Income stood at $1.9 million in 2020, then soared by 30.06% to $2.4 million in 2021, then spiked by 30.32% to $3.1 million in 2022, then tumbled by 71.81% to $887,000 in 2023, then crashed by 158.29% to -$517,000 in 2024.